Myovant: Drug Offers ‘Best-in-Class’ Potential

 Comments Off on Myovant: Drug Offers ‘Best-in-Class’ Potential
Nov 142017
 
Myovant: Drug Offers 'Best-in-Class' Potential

Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.

MTSL Issue 864

 Comments Off on MTSL Issue 864
Nov 122017
 
MTSL Issue 864

MTSL Issue 864 (dated 11/09/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ESPR #FPRX #INCY #IONS #MDCO #MYOV #NKTR #PCRX #SGMO #ZIOP